Literature DB >> 10551670

Myositis overlap syndromes.

Y Ioannou1, S Sultan, D A Isenberg.   

Abstract

Myositis-overlap syndromes are characterized by a heterogeneous group of clinical syndromes of which many are closely linked with specific autoantibodies. Clinical and laboratory-based research into this fascinating group of syndromes have given us clues in elucidating the role of immunogenetic, environmental influences on the etiopathogenesis of autoimmune disease. Patients positive for anti-snU1 RNP antibody often present with a constellation of "autoimmune-related" clinical features, often not fulfilling the diagnostic criteria for a single disease entity. Controversy remains as to whether this represents a single disease entity, namely mixed connective tissue disease, or an undifferentiated autoimmune rheumatic/overlap syndrome. Anti-PM-Scl antibodies are linked with myositis-scleroderma overlap and generally tend to follow a benign course, often responding well to minimal immunosuppression. More recently the number of anti-tRNA synthetase antibody-associated overlap syndromes has expanded; antibodies to the autoantigen histidyl-tRNA synthetase (Jo1) being the commonest and best characterized. Patients with these antibodies often have severe interstitial lung disease and the poorest prognosis, often necessitating aggressive immunosuppressive therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10551670

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  4 in total

Review 1.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

2.  Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens.

Authors:  William K Decker; Dongxia Xing; Sufang Li; Simon N Robinson; Hong Yang; David Steiner; Krishna V Komanduri; Elizabeth J Shpall
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

Review 3.  Dermatomyositis.

Authors:  M S Krathen; D Fiorentino; V P Werth
Journal:  Curr Dir Autoimmun       Date:  2008

4.  The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy.

Authors:  Ya-Mei Zhang; Han-Bo Yang; Jing-Li Shi; He Chen; Xiao-Ming Shu; Xin Lu; Guo-Chun Wang; Qing-Lin Peng
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.